Financing
998 thousand euros
Fondazione AIRC
Goal
The project aims to improve the understanding of the genetic and molecular mechanisms underlying pediatric acute myeloid leukemia (AML), the second most common form of leukemia in children. Through a precision medicine approach, the study seeks to develop new personalized therapeutic strategies capable of targeting cancer cells more selectively and effectively, while at the same time reducing the side effects of traditional therapies.
Development mode
The project is based on advanced genetic and molecular studies conducted on pediatric AML samples, with the aim of identifying specific biological alterations responsible for disease progression. The results obtained will make it possible to identify new therapeutic targets and to lay the groundwork for more targeted and innovative treatments.
The research will be carried out by Dr. Alice Giustacchini, a young researcher who has returned from abroad, within the framework of AIRC programs supporting Italian research talent. The funding will cover the costs of research activities, the salary of the principal researcher, and that of the staff involved in the project.